Close Menu

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Molecular diagnostics firm SIRS-Lab today announced a collaboration with Pfizer Pharma focused on sepsis diagnostics and treatment.

The firms will initially evaluate the clinical impact of using molecular-based tests for diagnosis of severe fungal blood stream infections, as well as the pharmacoeconomics of such an approach.

Financial and other terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports that US states and territories are seeking more funding for the distribution of SARS-CoV-2 vaccines.

The strain now accounts for about 80 percent of cases in Wales and Scotland, and about half of cases in England, the Guardian reports.

A new study suggests that using CRISPR to edit human embryonic DNA can lead to the loss of whole chromosomes, as the Associated Press reports.

In Science this week: ancient dog genomes highlight long ties with humans, genomic analysis of 40,000-year-old early East Asian individual, and more.

Nov
05
Sponsored by
Roche

This webinar will provide an overview of novel proximal and distal sampling methods that have promise to improve patient outcomes from esophageal cancer.

Nov
10
Sponsored by
LGC

The COVID-19 pandemic created a paradigm shift in modern healthcare, where regulations, protocols, and mindsets had to be reworked in just a matter of months to keep up with the pace of the virus.

Nov
17
Sponsored by
ACD

Circular RNAs (circRNAs) have recently gained substantial attention in the cancer research field where most, including the putative oncogene ciRS-7 (CDR1as), have been proposed to function as competitive endogenous RNAs (ceRNAs) by “sponging” specific microRNAs.

Nov
23
Sponsored by
Inivata

In non-small cell lung cancer (NSCLC), liquid biopsy allows detection of driver mutations and can shed light on the development of resistance mutations during treatment.